Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients’ quality of life

BACKGROUND: Although adjuvant gemcitabine (GEM) chemotherapy for pancreatic cancer is standard, the quality of life (QOL) in those patients is still impaired by the standard regimen of GEM. Therefore, we studied whether mild dose-intensity adjuvant chemotherapy with bi-weekly GEM administration coul...

Descripción completa

Detalles Bibliográficos
Autores principales: Toyama, Yoichi, Yoshida, Seiya, Saito, Ryota, Kitamura, Hiroaki, Okui, Norimitsu, Miyake, Ryo, Ito, Ryusuke, Son, Kyonsu, Usuba, Teruyuki, Nojiri, Takuya, Yanaga, Katsuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3548728/
https://www.ncbi.nlm.nih.gov/pubmed/23302293
http://dx.doi.org/10.1186/1477-7819-11-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3548728/
https://www.ncbi.nlm.nih.gov/pubmed/23302293
http://dx.doi.org/10.1186/1477-7819-11-3

Ejemplares similares